Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara®) in breast cancer patients
Identifieur interne : 000F07 ( Istex/Curation ); précédent : 000F06; suivant : 000F08Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara®) in breast cancer patients
Auteurs : Christian U. Pfister [Suisse] ; Antonio Martoni [Italie] ; Carlo Zamagni [Italie] ; Giorgio Lelli [Italie] ; Filippo De Braud [Italie] ; Claire Souppart [France] ; Martine Duval [France] ; Ulrike Hornberger [Suisse]Source :
- Biopharmaceutics & Drug Disposition [ 0142-2782 ] ; 2001-07.
English descriptors
Abstract
Letrozole (trademark Femara®) is a new orally active, potent and selective aromatase inhibitor for the hormonal treatment of advanced breast cancer in postmenopausal women. The pharmacokinetics of letrozole and the suppression of peripheral estrogens were studied in 28 breast cancer patients after a single dose and at steady state. The pharmacokinetics of two distinct age groups (⩾50, ⩽65, N=15 and ⩾70 years old, N=9) were compared. There were no significant differences in area under the curve (AUC) or terminal half‐life between the two age groups neither after a single dose nor at steady state. However, when comparing steady state to single dose kinetics, half‐life and AUC increased significantly by 42% (90% CI: 1.13, 1.78) and 28% (90% CI: 1.12, 1.47), respectively. This deviation from linearity was probably due to a partial saturation or auto‐inhibition of the dominant metabolic clearance mechanism of letrozole. At steady state, approximately 70% of the administered dose was excreted in urine as unchanged letrozole (6.0±3.8%) or as the glucuronide of the major, pharmacologically inactive metabolite CGP44645 (64.2±22.7%). A single dose of letrozole caused suppression of serum estrogen levels close to the quantification limit of the assay. No difference between single dose suppression and suppression at steady state could be detected. Copyright © 2001 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/bdd.273
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000F09
Links to Exploration step
ISTEX:B7DEAEFE4FB26865C52293911258A337A539C734Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara®) in breast cancer patients</title><author><name sortKey="Pfister, Christian U" sort="Pfister, Christian U" uniqKey="Pfister C" first="Christian U." last="Pfister">Christian U. Pfister</name><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma AG, Basel, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma AG, WSJ‐27.2.032, CH‐4002 Basel, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, WSJ‐27.2.032, CH‐4002 Basel</wicri:regionArea></affiliation></author><author><name sortKey="Martoni, Antonio" sort="Martoni, Antonio" uniqKey="Martoni A" first="Antonio" last="Martoni">Antonio Martoni</name><affiliation wicri:level="1"><mods:affiliation>Ospedale Policlinico, S. Orsola Malpighi, Bologna, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Ospedale Policlinico, S. Orsola Malpighi, Bologna</wicri:regionArea></affiliation></author><author><name sortKey="Zamagni, Carlo" sort="Zamagni, Carlo" uniqKey="Zamagni C" first="Carlo" last="Zamagni">Carlo Zamagni</name><affiliation wicri:level="1"><mods:affiliation>Ospedale Policlinico, S. Orsola Malpighi, Bologna, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Ospedale Policlinico, S. Orsola Malpighi, Bologna</wicri:regionArea></affiliation></author><author><name sortKey="Lelli, Giorgio" sort="Lelli, Giorgio" uniqKey="Lelli G" first="Giorgio" last="Lelli">Giorgio Lelli</name><affiliation wicri:level="1"><mods:affiliation>Ospedale Casa Sollievo della Sofferenza, S. Giovanni Rotondo (FG), Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Ospedale Casa Sollievo della Sofferenza, S. Giovanni Rotondo (FG)</wicri:regionArea></affiliation></author><author><name sortKey="De Braud, Filippo" sort="De Braud, Filippo" uniqKey="De Braud F" first="Filippo" last="De Braud">Filippo De Braud</name><affiliation wicri:level="1"><mods:affiliation>Istituto Europeo di Oncologia, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Europeo di Oncologia, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Souppart, Claire" sort="Souppart, Claire" uniqKey="Souppart C" first="Claire" last="Souppart">Claire Souppart</name><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma SA, Rueil‐Malmaison, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma SA, Rueil‐Malmaison</wicri:regionArea></affiliation></author><author><name sortKey="Duval, Martine" sort="Duval, Martine" uniqKey="Duval M" first="Martine" last="Duval">Martine Duval</name><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma SA, Rueil‐Malmaison, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma SA, Rueil‐Malmaison</wicri:regionArea></affiliation></author><author><name sortKey="Hornberger, Ulrike" sort="Hornberger, Ulrike" uniqKey="Hornberger U" first="Ulrike" last="Hornberger">Ulrike Hornberger</name><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma AG, Basel, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B7DEAEFE4FB26865C52293911258A337A539C734</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/bdd.273</idno><idno type="url">https://api.istex.fr/document/B7DEAEFE4FB26865C52293911258A337A539C734/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F09</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000F09</idno><idno type="wicri:Area/Istex/Curation">000F07</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara®) in breast cancer patients</title><author><name sortKey="Pfister, Christian U" sort="Pfister, Christian U" uniqKey="Pfister C" first="Christian U." last="Pfister">Christian U. Pfister</name><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma AG, Basel, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma AG, WSJ‐27.2.032, CH‐4002 Basel, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, WSJ‐27.2.032, CH‐4002 Basel</wicri:regionArea></affiliation></author><author><name sortKey="Martoni, Antonio" sort="Martoni, Antonio" uniqKey="Martoni A" first="Antonio" last="Martoni">Antonio Martoni</name><affiliation wicri:level="1"><mods:affiliation>Ospedale Policlinico, S. Orsola Malpighi, Bologna, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Ospedale Policlinico, S. Orsola Malpighi, Bologna</wicri:regionArea></affiliation></author><author><name sortKey="Zamagni, Carlo" sort="Zamagni, Carlo" uniqKey="Zamagni C" first="Carlo" last="Zamagni">Carlo Zamagni</name><affiliation wicri:level="1"><mods:affiliation>Ospedale Policlinico, S. Orsola Malpighi, Bologna, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Ospedale Policlinico, S. Orsola Malpighi, Bologna</wicri:regionArea></affiliation></author><author><name sortKey="Lelli, Giorgio" sort="Lelli, Giorgio" uniqKey="Lelli G" first="Giorgio" last="Lelli">Giorgio Lelli</name><affiliation wicri:level="1"><mods:affiliation>Ospedale Casa Sollievo della Sofferenza, S. Giovanni Rotondo (FG), Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Ospedale Casa Sollievo della Sofferenza, S. Giovanni Rotondo (FG)</wicri:regionArea></affiliation></author><author><name sortKey="De Braud, Filippo" sort="De Braud, Filippo" uniqKey="De Braud F" first="Filippo" last="De Braud">Filippo De Braud</name><affiliation wicri:level="1"><mods:affiliation>Istituto Europeo di Oncologia, Milan, Italy</mods:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Europeo di Oncologia, Milan</wicri:regionArea></affiliation></author><author><name sortKey="Souppart, Claire" sort="Souppart, Claire" uniqKey="Souppart C" first="Claire" last="Souppart">Claire Souppart</name><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma SA, Rueil‐Malmaison, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma SA, Rueil‐Malmaison</wicri:regionArea></affiliation></author><author><name sortKey="Duval, Martine" sort="Duval, Martine" uniqKey="Duval M" first="Martine" last="Duval">Martine Duval</name><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma SA, Rueil‐Malmaison, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma SA, Rueil‐Malmaison</wicri:regionArea></affiliation></author><author><name sortKey="Hornberger, Ulrike" sort="Hornberger, Ulrike" uniqKey="Hornberger U" first="Ulrike" last="Hornberger">Ulrike Hornberger</name><affiliation wicri:level="1"><mods:affiliation>Novartis Pharma AG, Basel, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Biopharmaceutics & Drug Disposition</title><title level="j" type="abbrev">Biopharm. Drug Dispos.</title><idno type="ISSN">0142-2782</idno><idno type="eISSN">1099-081X</idno><imprint><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2001-07">2001-07</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="191">191</biblScope><biblScope unit="page" to="197">197</biblScope></imprint><idno type="ISSN">0142-2782</idno></series><idno type="istex">B7DEAEFE4FB26865C52293911258A337A539C734</idno><idno type="DOI">10.1002/bdd.273</idno><idno type="ArticleID">BDD273</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0142-2782</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Femara</term><term>aromatase inhibitor</term><term>breast cancer patients</term><term>pharmacokinetics</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Letrozole (trademark Femara®) is a new orally active, potent and selective aromatase inhibitor for the hormonal treatment of advanced breast cancer in postmenopausal women. The pharmacokinetics of letrozole and the suppression of peripheral estrogens were studied in 28 breast cancer patients after a single dose and at steady state. The pharmacokinetics of two distinct age groups (⩾50, ⩽65, N=15 and ⩾70 years old, N=9) were compared. There were no significant differences in area under the curve (AUC) or terminal half‐life between the two age groups neither after a single dose nor at steady state. However, when comparing steady state to single dose kinetics, half‐life and AUC increased significantly by 42% (90% CI: 1.13, 1.78) and 28% (90% CI: 1.12, 1.47), respectively. This deviation from linearity was probably due to a partial saturation or auto‐inhibition of the dominant metabolic clearance mechanism of letrozole. At steady state, approximately 70% of the administered dose was excreted in urine as unchanged letrozole (6.0±3.8%) or as the glucuronide of the major, pharmacologically inactive metabolite CGP44645 (64.2±22.7%). A single dose of letrozole caused suppression of serum estrogen levels close to the quantification limit of the assay. No difference between single dose suppression and suppression at steady state could be detected. Copyright © 2001 John Wiley & Sons, Ltd.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F07 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000F07 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:B7DEAEFE4FB26865C52293911258A337A539C734
|texte= Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara®) in breast cancer patients
}}
| This area was generated with Dilib version V0.6.29. |  |